Status:
COMPLETED
Bifeprunox in the Treatment of Schizophrenia
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
Eligibility Criteria
Inclusion
- diagnosis of schizophrenia
- understand nature of study
- able to be managed in out-patient setting for long-term bifeprunox treatment
Exclusion
- current primary diagnosis other than schizophrenia
- suicide risk
- diagnosis or history of substance abuse
- uncontrolled hypertension
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00193713
Start Date
May 1 2005
End Date
November 1 2006
Last Update
January 16 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.